CoChat
Sign Up
Cited by 34Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record; 355 of the 355 references it cites were found in a registry or an index.

Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions

Archer, Trevor, Kostrzewa, Richard M., Beninger, Richard J., Palomo, Tomas·2011·Neurotoxicity Research
DOI 10.1007/s12640-010-9190-2
Open this paper in CoChat — free account

Abstract

The notion of staging in the neurodegenerative disorders is modulated by the constant and progressive loss of several aspects of brain structural integrity, circuitry, and neuronal processes. These destructive processes eventually remove individuals' abilities to perform at sufficient and necessary functional capacity at several levels of disease severity. The classification of (a) patients on the basis of diagnosis, risk prognosis, and intervention outcome, forms the basis of clinical staging, and (b) laboratory animals on the basis of animal model of brain disorder, extent of insult, and dysfunctional expression, provides the components for the clinical staging and preclinical staging, respectively, expressing associated epidemiological, biological, and genetic characteristics. The major focus of clinical staging in the present account stems from the fundamental notions of Braak staging as they describe the course and eventual prognosis for Alzheimer's disease, Lewy Body dementia, and Parkinson's disease. Mild cognitive impairment, which expresses the decline in episodic and semantic memory performance below the age-adjusted normal range without marked loss of global cognition or activities of daily living, and the applications of longitudinal magnetic resonance imaging, major instruments for the monitoring of either disease progression in dementia, present important challenges for staging concepts. Although Braak notions present the essential basis for further developments, current staging conceptualizations seem inadequate to comply with the massive influx of information dealing with neurodegenerative processes in brain, advanced both under clinical realities, and discoveries in the laboratory setting. The contributions of various biomarkers of disease progression, e.g., amyloid precursor protein, and neurotransmitter system imbalances, e.g., dopamine receptor supersensitivity and interactive propensities, await their incorporation into the existing staging models thereby underlining the ongoing, dynamic feature of the staging of brain disorders.

Overview

Integrity signals

Registry

Crossref · 10.1007/s12640-010-9190-2

Cites

355 of 355 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 355 references

Research works printed but not linked: 2

  1. Raz N (1996) Neuroanatomy of aging brain: evidence from structural MRI. In: Bigler ED (ed) Neuroimaging II: clinical application. Plenum Press, New York, pp 273–300
  2. Smith CD (2007) Mild cognition impairment is too late: the case for presymptomatic detection and treatment for Alzheimer’s disease. Cogn Sci 3:127–177

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Archer, T., Kostrzewa, R. M., Beninger, R. J., & Palomo, T.
Affiliations
  • University of Gothenburg (SE)
  • East Tennessee State University (US)
  • Queen's University (CA)
Corresponding author
Archer, Trevor
ORCID
Kostrzewa, Richard M.
Venue
Neurotoxicity Research
Publisher
Springer Science and Business Media LLC
Published
2010-04-15
Volume
19
Issue
2
Pages
211-234
ISSN
  • 1029-8428 (ISSN-L)
  • 1476-3524
DOI
10.1007/s12640-010-9190-2
OpenAlex
W2001174540
Cited by
34
References
355
Citations by year
2026: 3 · 2023: 3 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 8 · 2014: 3 · 2013: 4 · 2012: 3
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neurotoxicity Research (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons - East Tennessee State University (East Tennessee State University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Braak staging, Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, mild cognitive impairment, disease progression biomarkers, amyloid precursor protein, dopamine receptor supersensitivity, longitudinal MRI, animal models of neurodegeneration, brain structural integrity
MeSH terms
Animals, Humans, Biomarkers, Disease Progression, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review